Urology
Volume 75, Issue 3 , Pages 502-509 , March 2010

Reduction in the Risk of Prostate Cancer: Future Directions After the Prostate Cancer Prevention Trial

  • E. David Crawford

      Affiliations

    • Department of Urologic Oncology, University of Colorado Health Sciences Center, Denver, Colorado
    • Corresponding Author InformationReprint requests: E. David Crawford, MD, Division of Urologic Oncology, Departments of Surgery, Urology and Radiation Oncology, University of Colorado Health Sciences Center, Mail Stop #F710, PO Box #6510, Aurora, CO 80045
    • ,
  • Gerald L. Andriole

      Affiliations

    • Division of Urologic Surgery, Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri
    • ,
  • Michael Marberger

      Affiliations

    • Department of Urology, Medical University of Vienna, Vienna, Austria
    • ,
  • Roger S. Rittmaster

      Affiliations

    • Biomedical Data Sciences, GlaxoSmithKline, Research Triangle Park, North Carolina

Received 8 January 2009 ,Accepted 17 May 2009.

References 

  1. Andriole GL, Roehrborn C, Schulman C, et al. Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia. Urology. 2004;64:537–541
  2. Tindall DJ, Rittmaster RS. The rationale for inhibiting 5alpha-reductase isoenzymes in the prevention and treatment of prostate cancer. J Urol. 2008;179:1235–1242
  3. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349:215–224
  4. Thompson IM, Lucia MS, Redman MW, et al. Finasteride decreases the risk of prostatic intraepithelial neoplasia. J Urol. 2007;178:107–109
  5. Lucia MS, Epstein JI, Goodman PJ, et al. Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2007;99:1375–1383
  6. Canby-Hagino E, Hernandez J, Brand T, et al. Looking back at PCPT: looking forward to new paradigms in prostate cancer screening and prevention. Eur Urol. 2007;51:27–33
  7. Cohen YC, Liu KS, Heyden NL, et al. Detection bias due to the effect of finasteride on prostate volume: a modeling approach for analysis of the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2007;99:1366–1374
  8. Roehrborn CG, Lotan Y. The motion: prevention of prostate cancer with a 5alpha-reductase inhibitor is feasible. Eur Urol. 2006;49:396–400
  9. Goetzl MA, Holzbeierlein JM. Finasteride as a chemopreventive agent in prostate cancer: impact of the PCPT on urologic practice. Nat Clin Pract Urol. 2006;3:422–429
  10. Lucia S. Do 5 alpha-reductase inhibitors alter prostate cancer detection and what are the implications?. Eur Urol Suppl. 2006;5:752–757
  11. Serfling R, Shulman M, Thompson GL, et al. Quantifying the impact of prostate volumes, number of biopsy cores and 5alpha-reductase inhibitor therapy on the probability of prostate cancer detection using mathematical modeling. J Urol. 2007;177:2352–2356
  12. Kulkarni GS, Al-Azab R, Lockwood G, et al. Evidence for a biopsy derived grade artifact among larger prostate glands. J Urol. 2006;175:505–509
  13. Karakiewicz PI, Bazinet M, Aprikian AG, et al. Outcome of sextant biopsy according to gland volume. Urology. 1997;49:55–59
  14. King CR, Long JP. Prostate biopsy grading errors: a sampling problem?. Int J Cancer. 2000;90:326–330
  15. Briganti A, Chun FK, Suardi N, et al. Prostate volume and adverse prostate cancer features: fact not artifact. Eur J Cancer. 2007;43:2669–2677
  16. Freedland SJ, Isaacs WB, Platz EA, et al. Prostate size and risk of high-grade, advanced prostate cancer and biochemical progression after radical prostatectomy: a search database study. J Clin Oncol. 2005;23:7546–7554
  17. Thompson IM, Ankerst DP, Chi C, et al. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. J Am Med Assoc. 2005;294:66–70
  18. D'Amico AV, Barry MJ. Prostate cancer prevention and finasteride. J Urol. 2006;176:2010–2013
  19. Thompson IM, Chi C, Ankerst DP, et al. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst. 2006;98:1128–1133
  20. Redman MW, Tangen CM, Goodman PJ, et al. Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach. Cancer Prev Res. 2008;1:174–181
  21. Pinsky P, Parnes H, Ford L. Estimating rates of true High-Grade disease in the Prostate Cancer Prevention Trial. Cancer Prev Res. 2008;1:182–186
  22. Schroder FH, Roobol MJ, Andriole GL, et al. Defining increased future risk for prostate cancer: evidence from a population based screening cohort. J Urol. 2009;181:69–74
  23. Bhatnagar V, Stewart ST, Huynh V, et al. Estimating the risk of long-term erectile, urinary and bowel symptoms resulting from prostate cancer treatment. Prostate Cancer Prostatic Dis. 2006;9:136–146
  24. Grover SA, Coupal L, Zowall H, et al. The economic burden of prostate cancer in Canada: forecasts from the Montreal prostate cancer model. CMAJ. 2000;162:987–992
  25. Issa MM, Fenter TC, Black L, et al. An assessment of the diagnosed prevalence of diseases in men 50 years of age or older. Am J Manag Care. 2006;12:S83–S89
  26. Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008;358:1250–1261
  27. Earle CC, Chapman RH, Baker CS, et al. Systematic overview of cost-utility assessments in oncology. J Clin Oncol. 2000;18:3302–3317
  28. Svatek RS, Lee JJ, Roehrborn CG, et al. The cost of prostate cancer chemoprevention: a decision analysis model. Cancer Epidemiol Biomarkers Prev. 2006;15:1485–1489
  29. Unger JM, Thompson IM, LeBlanc M, et al. Estimated impact of the Prostate Cancer Prevention Trial on population mortality. Cancer. 2005;103:1375–1380
  30. Zeliadt SB, Etzioni RD, Penson DF, et al. Lifetime implications and cost-effectiveness of using finasteride to prevent prostate cancer. Am J Med. 2005;118:850–857
  31. Svatek RS, Lee JJ, Roehrborn CG, et al. Cost-effectiveness of prostate cancer chemoprevention: a quality of life-years analysis. Cancer. 2008;112:1058–1065
  32. Roddam AW, Allen NE, Appleby P, et al. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst. 2008;100:170–183
  33. Parekh DJ, Ankerst DP, Higgins BA, et al. External validation of the Prostate Cancer Prevention Trial risk calculator in a screened population. Urology. 2006;68:1152–1155
  34. Gleave M, Qian J, Andreou C, et al. The effects of the dual 5alpha-reductase inhibitor dutasteride on localized prostate cancer: results from a 4-month pre-radical prostatectomy study. Prostate. 2006;66:1674–1685
  35. Peters U, Littman AJ, Kristal AR, et al. Vitamin E and selenium supplementation and risk of prostate cancer in the vitamins and lifestyle (VITAL) study cohort. Cancer Causes Control. 2008;19:75–87
  36. Lippman SM, Klein EA, Goodman PJ, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the selenium and vitamin E Cancer Prevention Trial (SELECT). J Am Med Assoc. 2009;301:39–51
  37. Thompson IM. Chemoprevention of prostate cancer: agents and study designs. J Urol. 2007;178:S9–S13
  38. Price D, Stein B, Sieber P, et al. Toremifene for the prevention of prostate cancer in men with high grade prostatic intraepithelial neoplasia: results of a double-blind, placebo controlled, phase IIB clinical trial. J Urol. 2006;176:965–970
  39. Andriole G, Bostwick D, Brawley O, et al. Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial. J Urol. 2004;172:1314–1317
  40. Thomas LN, Lazier CB, Gupta R, et al. Differential alterations in 5alpha-reductase type 1 and type 2 levels during development and progression of prostate cancer. Prostate. 2005;63:231–239
  41. Titus MA, Gregory CW, Ford OH, et al. Steroid 5alpha-reductase isozymes I and II in recurrent prostate cancer. Clin Cancer Res. 2005;11:4365–4371
  42. Frye SV. Discovery and clinical development of dutasteride, a potent dual 5alpha-reductase inhibitor. Curr Top Med Chem. 2006;6:405–421
  43. Andriole GL, Humphrey P, Ray P, et al. Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer. J Urol. 2004;172:915–919
  44. Clark RV, Hermann DJ, Cunningham GR, et al. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor. J Clin Endocrinol Metab. 2004;89:2179–2184
  45. Xu Y, Dalrymple SL, Becker RE, et al. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers. Clin Cancer Res. 2006;12:4072–4079
  46. Andriole G. Further Analyses from the REDUCE Prostate Cancer Risk Reduction Trial. Abstract LBA1. American Urological Association Annual Meeting. Chicago, United States 2009;
  47. Roehl KA, Antenor JA, Catalona WJ. Serial biopsy results in prostate cancer screening study. J Urol. 2002;167:2435–2439
  48. Djavan B, Ravery V, Zlotta A, et al. Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop?. J Urol. 2001;166:1679–1683
  49. Fang J, Metter EJ, Landis P, et al. Low levels of prostate-specific antigen predict long-term risk of prostate cancer: results from the Baltimore longitudinal study of aging. Urology. 2001;58:411–416
  50. Thomas LN, Douglas RC, Lazier CB, et al. Levels of 5alpha-reductase type 1 and type 2 are increased in localized high grade compared to low grade prostate cancer. J Urol. 2008;179:147–151

 Medical writing support in the preparation of this manuscript was provided by Katherine Carpenter and was funded by GlaxoSmithKline.

PII: S0090-4295(09)00931-5

doi: 10.1016/j.urology.2009.05.099

Urology
Volume 75, Issue 3 , Pages 502-509 , March 2010

Article Tools

* Image Usage & Resolution